Table 2.

Significantly altered metabolites, detected by LC-MS, between patients with prostate cancer and healthy control subjects.

Category	Compound	ESI Mode	m/z	RT	%Δ	FC	log2FC	pBH	VIP
Fatty Acyls	Thapsic acid (hexadecanedioic acid)	-	285.2072	16.30	138.00	2.38	1.25	<0.0001	1.47
	Methylhexadecenoic acid	+	269.2461	18.70	86.68	1.87	0.90	<0.0001	1.05
	Palmitoleic acid	-	253.2176	27.60	88.09	1.88	0.91	<0.0001	1.14
	Linolenic acid (octadecatrienoic acid)	-	277.2174	25.90	91.04	1.91	0.93	<0.0001	1.12
	Oleic acid	-	281.2493	31.45	80.58	1.81	0.85	<0.0001	1.03
	Eicosapentaenoic acid	+	303.2313	25.54	252.02	3.52	1.82	<0.0001	1.19
	Docosapentaenoic acid	-	329.2488	28.63	103.96	2.04	1.03	<0.0001	1.19
	Decadienal	+	153.1267	12.45	−30.21	0.70	−0.52	<0.0001	0.28
	Octadecadienal (9,12)	+	265.2508	25.92	146.52	2.47	1.30	<0.0001	2.78
	Tetradecenoylcarnitine	+	370.2963	12.70	113.97	2.14	1.10	<0.0001	1.01
	9-hydroxyoctadecadienoic acid (9-HODE)	-	295.2278	18.71	388.27	4.88	2.29	<0.0001	3.97
Glycerolipids	MG(16:0)	+	331.2855	27.69	246.30	3.46	1.79	<0.0001	1.55
	MG(18:0)	+	359.3155	32.05	2966.39	30.66	4.94	<0.0001	6.00
	MG(18:2(9,12))	+	355.2844	25.33	238.69	3.39	1.76	<0.0001	1.23
Organic acids and derivatives	Arginine	+	175.1190	0.57	62.43	1.62	0.70	<0.0001	1.37
	Threonylhistidine	-	255.1121	1.79	91.05	1.91	0.93	<0.0001	1.57
	O-methoxycatechol-O-sulphate	-	203.0025	1.51	−71.64	0.28	−1.82	<0.0001	1.59
	Pyrocatechol sulfate	-	188.9878	1.19	−80.33	0.20	−2.35	<0.0001	3.47
Organoheterocyclic compounds	Biliverdin	+	583.2551	9.90	180.27	2.80	1.49	<0.0001	1.10
Prenol Lipids	Retinal	+	285.2222	25.55	754.02	8.54	3.09	<0.0001	2.91
Sterol Lipids	Hyodeoxycholic acid	-	391.2841	15.03	−83.22	0.17	−2.57	<0.0001	3.60
	Pregnenolone	+	317.2472	25.56	653.97	7.54	2.91	<0.0001	1.66

%Δ, percentage of change; FC, fold change; pBH, Benjamini–Hochberg adjusted p-value; RT, retention time; VIP, variable importance in the projection.